After initially refusing to even review it, the US Food and Drug Administration (FDA) has approved Moderna's mRNA seasonal flu vaccine, the pharmaceutical company announced in a press release. However, it added that "solicited adverse events" were more frequent with mRNA-1010 than current flu vaccines, including injection-site pain, fatigue, headache and myalgia (muscle pain). Approval for Moderna's flu vaccine got off to a rocky start after the FDA refused to even review Moderna's application. The FDA's refusal to review the vaccine came after the director of drug approval overruled career scientists, prompting critics to call the move political. After less than a week, however, the FDA reversed course and agreed to review Moderna's application, likely because it previously told Moderna that its selected comparator vaccine was just fine.